NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 9, 2020–...
SutroVax Announces Name Change to Vaxcyte
Foster City, Calif., May 21, 2020 – SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel...
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
SOUTH SAN FRANCISCO, Calif., May 21, 2020– Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focusedon the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards – Carlos Paya, MD, PhD, and Lainie Martin, MD
SOUTH SAN FRANCISCO, Calif., May 21, 2020– Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focusedon the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
South San Francisco, Calif., May 14, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad...
Sutro Biopharma Announces Pricing of $85.3 Million Public Offering
South San Francisco, Calif., May 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad...
Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments
STRO-002 Encouraging Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Presented at the AACR Virtual Meeting STRO-001 Phase 1 Clinical Trial and Dose Escalation Ongoing in Multiple Myeloma and Lymphoma Merck Extends Research Term of...
Sutro Biopharma Announces Proposed Public Offering
South San Francisco, Calif., May 11, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad...
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients saw a reduction in CA-125 levels of 50% or more or a normalization of CA-125 levels - 35% of patients who were evaluable for progression have...
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
-Company to present updated STRO-002 data at AACR Virtual Annual Meeting - SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
